Get the Stockscreener App
125.20
0.77%
-1.0029
Illumina Inc stock is traded at $125.20, with a volume of 502.09K.
It is down -0.77% in the last 24 hours and down -1.70% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$126.20
Open:
$125.27
24h Volume:
502.09K
Relative Volume:
0.25
Market Cap:
$19.14B
Revenue:
$4.34B
Net Income/Loss:
$850.00M
P/E Ratio:
22.92
EPS:
5.4635
Net Cash Flow:
$921.00M
1W Performance:
-1.07%
1M Performance:
-1.70%
6M Performance:
+36.58%
1Y Performance:
+51.19%
1-Day Range:
$124.69
$127.30
1-Week Range:
$122.04
$128.74
52-Week Range:
$68.70
$155.53
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
125.17 | 19.30B | 4.34B | 850.00M | 921.00M | 5.4635 |
TMO
Thermo Fisher Scientific Inc
|
490.10 | 182.31B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
188.07 | 132.34B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
574.00 | 45.84B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
113.74 | 31.93B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
302.33 | 29.66B | 3.17B | 642.63M | 516.49M | 10.77 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jul-11-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Argus raises Illumina stock price target to $145 on new products - Investing.com
Illumina Inc. stock navigates Grail divestiture challenges amid biotech sector pressures - AD HOC NEWS
Illumina Inc stock faces headwinds amid Grail divestiture and biotech sector pressures - AD HOC NEWS
Short Squeeze: Will Illumina Inc benefit from seasonality2026 Closing Moves & Weekly Top Gainers Trade List - baoquankhu1.vn
Illumina Inc. stock faces ongoing challenges from Grail divestiture and genomics market pressures - AD HOC NEWS
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Illumina Inc. stock faces headwinds amid Grail divestiture scrutiny and biotech sector slowdown - AD HOC NEWS
Illumina price gives in to negative pressureForecast today24-03-2026 - Economies.com
US Multiomic Market Set to Boom Rapidly, Witnessing Strong - openPR.com
Illumina : CSR Report (2025 illumina france gender pay gap english) - marketscreener.com
Illumina : CSR Report (2025 illumina gender pay gap uk) - marketscreener.com
A $175 Million Move Into Sotera Health Signals Potential Opportunity Amid 21% Stock Drop - The Motley Fool
Prediction Tool Market Poised for Rapid Growth as AI and Genomics - openPR.com
Canaccord reiterates Hold on Illumina stock amid Roche competition - Investing.com
Nordea Investment Management AB Boosts Stake in Illumina - National Today
Nordea Investment Management AB Has $124.15 Million Stake in Illumina, Inc. $ILMN - MarketBeat
Illumina TruPath™ Genome supports a more comprehensive genome analysis - Illumina
Illumina Inc. stock faces renewed scrutiny amid Grail divestiture delays and biotech sector headwind - AD HOC NEWS
Illumina Introduces a New AI algorithm PromoterAI: Stock to Gain? - MSN
Swiss Life Asset Management Ltd Purchases 67,772 Shares of Illumina, Inc. $ILMN - MarketBeat
Here’s Why Illumina Could Continue Its 47% Last Year Rally - TIKR.com
Illumina, Inc. (NASDAQ:ILMN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Illumina Inc. stock underperforms Friday when compared to competitors - MarketWatch
Illumina and Labcorp Expand Precision Oncology Testing Partnership - Oncodaily
Illumina, Inc. $ILMN Shares Sold by CIBC Private Wealth Group LLC - MarketBeat
Illumina Says China Removed Ban on Importing DNA Sequencers - MSN
ILMN Stock Gains Following Expanded Collaboration With Labcorp - TradingView
In Canada, researching the use of AI to accelerate answers for rare disease - Illumina
DNA Sequencing Market size to hit $108.95 Billion by 2035 | Top - openPR.com
JPMorgan Chase Boosts Illumina Stake by 17.5% - National Today
JPMorgan Chase & Co. Acquires 124,246 Shares of Illumina, Inc. $ILMN - MarketBeat
ILMN Stock Price, Quote & Chart | ILLUMINA INC (NASDAQ:ILMN) - ChartMill
Illumina and Labcorp expand cancer testing collaboration - Investing.com India
Illumina, Labcorp Expand Collaboration to Advance Precision Oncology Testing - marketscreener.com
Synthetic Biology Market to Reach US$ 67.47 Billion by 2033 | - openPR.com
Life Sciences Tools & Services Stocks Q4 Earnings: Illumina (NASDAQ:ILMN) Firing on All Cylinders - Yahoo Finance
Illumina and Labcorp expand collaboration to broaden access to precision oncology testing - PR Newswire
Investment Report: Is Illumina Inc stock a good dividend stockPortfolio Update Report & Weekly Breakout Watchlists - baoquankhu1.vn
U.S. Bioinformatics Market Is Booming Rapidly with Strong - openPR.com
Illumina Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Gotham Asset Management LLC Purchases 144,475 Shares of Illumina, Inc. $ILMN - MarketBeat
How Illumina’s Genomics Insurance Push And Multiomic Alliance Expansion At Illumina (ILMN) Has Changed Its Investment Story - simplywall.st
Illumina Adds Activist to Board, Names Former FDA Chief as Chair - MSN
Illumina partners with Veritas Genetics to advance preventive genomics - National Today
Illumina Stock: Here’s Why Numbers Suggest a 63% Upside - TIKR.com
Illumina partners with Veritas to offer genome sequencing via insurers - Investing.com
Illumina advances preventive genomics through strategic consortium with Veritas Genetics - Finansavisen
Illumina, Inc. $ILMN Shares Sold by Ion Asset Management Ltd. - MarketBeat
Bamco Inc. NY Sells 39,378 Shares of Illumina, Inc. $ILMN - National Today
Illumina, Inc. $ILMN Stake Lessened by Cannell & Spears LLC - MarketBeat
Illumina, Inc. $ILMN Shares Sold by Casdin Capital LLC - MarketBeat
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):